ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

8,395Medicare Part D Prescriptions Filled, Including Refills

Rank: 126 out of 807

$457K Total Retail Price of All Prescriptions

Rank: 156 out of 807

523 Patients Receiving at Least One Drug in Part D
91%Patients 65 Years and Older
10% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Minnesota
Lower avg

Schedule Two
Controlled Substances

4% of this provider’s 523 patients filled at least one prescription for a schedule two drug, compared to an average of 5%.

Schedule Three
Controlled Substances

11% of this provider’s 523 patients filled at least one prescription for a schedule three drug, compared to an average of 6%.

Risky Drugs to Seniors

1% of this provider’s 7,720 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

21% of this provider’s prescriptions were for brand-name drugs, compared to an average of 22%.

Prescription Price

$54 was the average price of a prescription from this provider, compared to $58 among peers.

Prescriptions per Patient

16 is the average number of prescriptions (including refills) per patient, compared to an average of 16.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Minnesota
SIMVASTATIN 510 491 1 1
AMLODIPINE BESYLATE 337 321 2 5
LISINOPRIL 289 258 3 2
ATENOLOL 272 250 4 7
LEVOTHYROXINE SODIUM 272 256 4 3
ATORVASTATIN CALCIUM 249 237 6 11
FUROSEMIDE 172 165 7 6
WARFARIN SODIUM 169 166 8 10
OMEPRAZOLE 168 163 9 4
LOSARTAN POTASSIUM 137 133 10 14
HYDROCODONE-ACETAMINOPHEN 130 78 S3 11 15
ZOLPIDEM TARTRATE 120 118 12 23
TAMSULOSIN HCL 118 115 13 27
METOPROLOL SUCCINATE 114 114 14 13
ALLOPURINOL 107 105 15 26
POTASSIUM CHLORIDE 104 104 16 18
ATENOLOL-CHLORTHALIDONE 103 99 17 132
LISINOPRIL-HYDROCHLOROTHIAZIDE 100 80 18 28
ALENDRONATE SODIUM 97 84 19 20
LOSARTAN-HYDROCHLOROTHIAZIDE 92 87 20 55
FINASTERIDE 91 89 21 89
CITALOPRAM HBR 86 79 22 17
METFORMIN HCL 85 85 23 12
PLAVIX 84 79 24 60
SERTRALINE HCL 83 83 25 22
TRAMADOL HCL 83 51 25 19
CRESTOR 83 82 25 32
PREDNISONE 78 63 28 24
DIOVAN 76 76 29 46
GLIMEPIRIDE 74 73 30 51
TRIAMTERENE-HCTZ 74 74 30 29
DIGOXIN 71 71 32 41
PRAVASTATIN SODIUM 69 58 33 21
HYDROCHLOROTHIAZIDE 68 65 34 9
FLUTICASONE PROPIONATE 67 63 35 30
CLOPIDOGREL 67 58 35 47
ACETAMINOPHEN-CODEINE 67 55 S3 35 93
DONEPEZIL HCL 66 66 38 31
DOXAZOSIN MESYLATE 65 53 39 70
TRAZODONE HCL 63 57 40 25
LIPITOR 60 58 41 100
METOPROLOL TARTRATE 59 57 42 8
GABAPENTIN 56 46 43 16
CIPROFLOXACIN HCL 54 53 44 72
JANUVIA 54 51 44 79
DILTIAZEM ER 53 48 46 109
AZITHROMYCIN 50 49 47 57
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Oct. 7, 2014.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.